MGC Pharmaceuticals has reported record sales for March from its pharmaceutical grade phytomedicine products, its MP product line in Australia driving the company’s best monthly result to date with more than 1,500 units sold.
Global chief sales officer Nicole Godresse said: “In recent months we have seen rapid sales growth of our medical cannabis products as a direct result of our strategy to broaden our core prescriber base, diversify and expand our revenue streams and build additional strategic alliances.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.